healthcare communications

Dr. Cathy Kapica's picture

Consuming Bugs the Modern Way: Probiotics, Prebiotics, and Synbiotics

0 comments

Digestive health is a current hot topic, and it is [[wysiwyg_imageupload:118:]]
expected to remain so for the next few years. The role of gaining or maintaining a healthy intestinal microflora (bacteria) is a key factor for digestive health, not to mention the potential impact it has on our overall health. So, the rise in probiotics, prebiotics and synbiotics is no surprise and – since this is such a hot topic that affects our everyday lives, balance and general feeling of well-being – people have a greater understanding of the presence and meaning of these “biotics” in their diet.

Oh, wait. That would be in a perfect world. The reality is that this new (actually old) entry into our diets is complex. When people assess their dietary habits, they need simple solutions; identifying and isolating beneficial biotics that work sounds more than a little daunting. As communicators, we have the opportunity to make the garden of microflora simple for all consumers. And that starts with an understanding of the basics. Read full post »

Suzannah Palinkas's picture

We Must First Ask the Question - What Do We Want to Accomplish?

0 comments

It seems simple enough and a logical first step to [[wysiwyg_imageupload:114:]]
planning anything but so many times, across multiple disciplines, we hear:

“We need a Facebook page.”

“We need to have a blog.”

“We need to be Tweeting.”

But why? At a recent social media conference, specifically in the Pharma space, the question and principle came up multiple times… we need to start by asking a few simple questions. What are we trying to accomplish? Reaching who? What then are we going to do with the information? Why do we need to be in the social media space?

One can’t deny that online vehicles are growing rapidly, exponentially expanding, and that social media channels are just too large a communication vehicle to ignore. Even so, there has to be the right fit between what a company wants to accomplish online and the vehicles through which it achieves those goals. And it seems that sometimes those key questions haven’t been answered, and the result is an inappropriate or useless execution that simply checks a box. Read full post »

Suzannah Palinkas's picture

Corporate Social Responsibility (Not That Kind)

0 comments

According to Wikipedia, Corporate Social [[wysiwyg_imageupload:112:]]
Responsibility (CSR) is described as “embracing responsibility and encouraging a positive impact through a company’s activities on the environment, consumers, employees, communities, stakeholders and all other members of the public sphere.” Perhaps we should reconsider this description and think of those words as they relate to Pharma in the online/social media space.

During a recent conference on the social/digital space, there were many examples of how Pharma can engage online. But, even with the positive examples given at the conference, our day-to-day experience can paint a different picture. Stung by warnings and violation letters, the Pharma world is very cautious of talking about their company, let alone a product, in the social media space. Read full post »

Diane R. Johnson, MPH's picture

The New Real World: Transparency and Innovation in Government

0 comments

With the 24-hour news cycle, new and social [[wysiwyg_imageupload:109:]]
media at our fingertips, and even a presidential initiative on “transparency and open government” — federal agencies must adapt to this change in paradigm. The Food and Drug Administration (FDA) along with the Centers for Medicare & Medicaid Services (CMS) recently held a summit in Washington, DC, where its top policy makers engaged biotech and pharmaceutical executives in an open dialogue on driving pre- and post-regulatory approval and commercialization strategies for products coming to market. Read full post »

Alexander Watson's picture

PR and Patent Cliffs 2012: Could We Be Seeing the End of “Big Pharma” as We Know It?

2 comments

[[wysiwyg_imageupload:108:]]As patent cliffs continue to crack and crumble into the sea and send shock waves through big pharma around the world, global healthcare PR strategists continue to train their skilled teams’ eyes and ears on the future trends of big pharma, urgently trying to discern the shape of the new emerging landmass to keep ahead of the game.

Over the next three years, six Big Pharma companies have more than half of their portfolio at risk due to patent expirations.  I’d imagine that this creates anxiety among communications agencies around the world asking what this all means for them and future revenue streams. Should we start prophesying that the end is nigh for “big pharma”? Long-term, can viable business models continue to be sustained around portfolios of products that have such short patent shelf lives? Read full post »